---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-043141"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:21:57.522900+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Cocrystal Pharma highlights in vitro activity of CC-42344 against avian H5N1, Phase 2a data expected by end of 2024

## Summary
- CC-42344 showed in vitro activity against avian influenza A (H5N1) PB2 protein; high-resolution crystal structure confirmed binding.
- Phase 2a human challenge study for seasonal influenza A topline safety/tolerability results expected by end of 2024.
- Phase 1 study of pan-viral candidate CDI-988 for noroviruses and coronaviruses; topline data expected late 2024 or early 2025.
- No approved vaccine or antiviral for norovirus; estimated 685M cases and 200K deaths annually worldwide (CDC).
- Preparations underway for US IND application for late-stage study of CC-42344.

## SEC filing metadata
- accession: 0001493152-24-043141
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315224043141/0001493152-24-043141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315224043141/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-043141
- JSON: https://secwatch.observer/filing/0001493152-24-043141.json
- Plain text: https://secwatch.observer/filing/0001493152-24-043141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.